Literature DB >> 25658176

COMPARISON OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS AND CLINICAL REVIEW STRATEGIES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Robert J Courtney1, Jedediah I McClintic, Justis P Ehlers.   

Abstract

PURPOSE: To compare various spectral domain optical coherence tomography scan patterns and review strategies to identify an optimal imaging workflow for neovascular age-related macular degeneration.
METHODS: A retrospective consecutive case series was performed in eyes after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration with concurrent spectral domain optical coherence tomography imaging (Zeiss Cirrus), including horizontal/vertical five-line rasters, and macular cube analysis. For each scan pattern, a single report was independently reviewed in a masked fashion within the clinical image review software, whereas the cube was reviewed line-by-line in the reader software for the presence of fluid.
RESULTS: One hundred and fifty-six reports and 39 cube scans of 39 patients were included. Among all spectral domain optical coherence tomography scans, 64% (25/39) had definitive fluid and 95% (37/39) had possible fluid. Sensitivities for definite fluid detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 68%, 76%, and 88%, respectively. When assessing for possible fluid, sensitivities for the detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 76%, 92%, and 97%, respectively. Line-by-line review of the cube scan had a sensitivity for definite and possible fluid detection of 96% and 86%, respectively.
CONCLUSION: Optimizing both clinical accuracy and workflow are important factors in managing neovascular age-related macular degeneration. A zero-tolerance strategy with vertical/horizontal raster scans and thickness maps was comparable with line-by-line review of the cube to detect possible fluid.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25658176      PMCID: PMC4478143          DOI: 10.1097/IAE.0000000000000478

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Comparison of retinal thickness measurements between three-dimensional and radial scans on spectral-domain optical coherence tomography.

Authors:  Kaori Sayanagi; Sumit Sharma; Peter K Kaiser
Journal:  Am J Ophthalmol       Date:  2009-06-03       Impact factor: 5.258

2.  Optical coherence tomography.

Authors:  D Huang; E A Swanson; C P Lin; J S Schuman; W G Stinson; W Chang; M R Hee; T Flotte; K Gregory; C A Puliafito
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

3.  Sensitivity of fluid detection in patients with neovascular amd using spectral domain optical coherence tomography high-definition line scans.

Authors:  Jennifer E De Niro; H Richard McDonald; Robert N Johnson; J Michael Jumper; Arthur D Fu; Emmett T Cunningham; Brandon J Lujan
Journal:  Retina       Date:  2014-06       Impact factor: 4.256

4.  Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization.

Authors:  Andrea Giani; Cristiano Luiselli; Daniel D Esmaili; Paola Salvetti; Mario Cigada; Joan W Miller; Giovanni Staurenghi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-07-29       Impact factor: 4.799

5.  Is quantitative spectral-domain superior to time-domain optical coherence tomography (OCT) in eyes with age-related macular degeneration?

Authors:  Urban Eriksson; Albert Alm; Eva Larsson
Journal:  Acta Ophthalmol       Date:  2011-03-04       Impact factor: 3.761

6.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

7.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

8.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

9.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

10.  Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity.

Authors:  James C Major; Charles C Wykoff; Angeline F Mariani; Eric Chen; Daniel E Croft; David M Brown
Journal:  Retina       Date:  2014-01       Impact factor: 4.256

View more
  3 in total

Review 1.  [Quality assurance of optical coherence tomography for diagnostics of the fundus : Positional statement of the BVA, DOG and RG].

Authors: 
Journal:  Ophthalmologe       Date:  2017-07       Impact factor: 1.059

2.  Multiple scan averaging to yield accurate quantitative analysis of optical coherence tomography angiograms.

Authors:  Hafi M Khan; Alex Gentle; James A Armitage; Chi-Ho To; Andrew K C Lam
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

3.  Comparison of OCT Angiography Review Strategies to Identify Vascular Abnormalities in the AVATAR Study.

Authors:  Amy S Babiuch; Mehnaz Khan; Ming Hu; Peter K Kaiser; Sunil K Srivastava; Rishi P Singh; Allison Watts; Jamie L Reese; Justis P Ehlers
Journal:  Ophthalmol Retina       Date:  2018-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.